Lung valves could starve Drug-Resistant TB cavities

NCT ID NCT07296055

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether placing one-way valves in the lungs can shrink cavities caused by drug-resistant tuberculosis (TB) or nontuberculous mycobacteria (NTM) infections. The valves block airflow into the cavity, creating a low-oxygen environment that may slow or stop bacterial growth. Thirty adults with cavities that cannot be surgically removed will be randomly assigned to receive either standard medical therapy alone or standard therapy plus the valve. The goal is to see if the valve helps reduce cavity size and clear bacteria from sputum after 9 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIDRUG RESISTANCE TUBERCOLOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

extensively drug-resistant tuberculosis multidrug-resistant tuberculosis pulmonary non-tuberculous mycobacterial infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Azienda Ospedaliera Universitaria Careggi

    Florence, FI, 50134, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Email: •••••@•••••

    Contact